Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients

NCT03771183 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT03771183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03771183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients
Lead sponsor
Centre Jean Perrin
Phase
Observational
Overall status
Completed
Start date
August 23, 2019
Completion date
February 28, 2021
Enrollment
97 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer patients, therapy related tumor